Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
32.87
-0.53 (-1.59%)
Jun 20, 2025, 4:00 PM - Market closed
Vaxcyte Stock Forecast
Stock Price Forecast
The 10 analysts that cover Vaxcyte stock have a consensus rating of "Strong Buy" and an average price target of $136.5, which forecasts a 315.27% increase in the stock price over the next year. The lowest target is $90 and the highest is $163.
Price Target: $136.5 (+315.27%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Vaxcyte stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 22, 2025 |
| Needham | Needham | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +173.81% | Apr 8, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $138 → $100 | Strong Buy | Maintains | $138 → $100 | +204.23% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $157 → $137 | Strong Buy | Maintains | $157 → $137 | +316.79% | Apr 1, 2025 |
| Needham | Needham | Strong Buy Maintains $140 → $90 | Strong Buy | Maintains | $140 → $90 | +173.81% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.67B
Revenue Next Year
n/a
EPS This Year
-4.84
from -3.80
EPS Next Year
-5.21
from -4.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 346.5M | ||
| Avg | n/a | n/a | 77.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.32 | -4.24 | -4.15 | ||
| Avg | -4.84 | -5.21 | -5.29 | ||
| Low | -5.36 | -5.57 | -6.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.